On February 23, 2016, President-elect Tsai Ing-Wen met with pharmaceutical industry leaders at the Nankang Software Park. Together with R&D directors from Oneness Biotech and Fountain Biopharma, Microbio Group Chairman William Lu presented the drug discovery joint laboratories and explained the Group’s R&D pipeline to President-elect Tsai and Vice President-elect Chen Chien-Jen. Microbio Group’s R&D pipeline currently contains 10 innovative drugs, of which 2 have obtained regulatory approvals and 8 are under clinical development with 6 IND approvals from the US FDA.